KPIs & Operating Metrics(New)
Growth Metrics

Abbott Laboratories (ABT) Payables (2016 - 2026)

Abbott Laboratories' Payables history spans 18 years, with the latest figure at $5.8 billion for Q1 2026.

  • On a quarterly basis, Payables rose 10.16% to $5.8 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $5.8 billion, a 10.16% increase, with the full-year FY2025 number at $5.3 billion, up 2.26% from a year prior.
  • Payables hit $5.8 billion in Q1 2026 for Abbott Laboratories, up from $5.3 billion in the prior quarter.
  • Over the last five years, Payables for ABT hit a ceiling of $5.8 billion in Q1 2026 and a floor of $4.8 billion in Q3 2023.
  • Historically, Payables has averaged $5.2 billion across 5 years, with a median of $5.2 billion in 2024.
  • Biggest five-year swings in Payables: increased 10.17% in 2022 and later dropped 9.42% in 2023.
  • Tracing ABT's Payables over 5 years: stood at $5.5 billion in 2022, then dropped by 4.44% to $5.2 billion in 2023, then decreased by 0.59% to $5.2 billion in 2024, then rose by 2.26% to $5.3 billion in 2025, then grew by 8.28% to $5.8 billion in 2026.
  • Business Quant data shows Payables for ABT at $5.8 billion in Q1 2026, $5.3 billion in Q4 2025, and $5.2 billion in Q3 2025.